The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Autism Research Program (ARP) -- Clinical Translational Research Award
The ARP Clinical Translational Research Award is intended to support early-phase, proof-ofprinciple translational studies that will examine hypothesis-based, innovative interventions/ clinical research that has the potential to address current clinical deficits for ASD. Applications are strongly encouraged to address one of the FY21 ARP Clinical Translational Research Award Areas of Interest. If the proposed project does not address any of the FY21 ARP Clinical Translational Research Award Areas of Interest, the application should describe how the project will nevertheless address another critical problem or issue in ASD. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform ASD clinical care.
Principal Investigators (PIs) seeking funding for a larger clinical trial should consider the ARP Clinical Trial Award (Funding Opportunity Number W81XWH-21-ARP-CTA). Similarly, PIs seeking funding for a preclinical research project should consider the ARP Idea Development Award (Funding Opportunity Number W81XWH-21-ARP-IDA).
• Required Pre-Application Deadline: May 3, 2021
• Invitation to Submit an Application: June 2021
• Application Submission Deadline: August 5, 2021
Areas of Interest
The FY21 ARP Clinical Translational Research Award seeks applications for early-phase clinical research. The ARP encourages applications that address the critical needs of the ASD community in one or more of the following areas: • Dissemination/implementation of clinically validated interventions • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions • Improve diagnosis and access to services across the life span • Interventions promoting success in key transitions to adulthood for individuals living with ASD • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services • Understanding heterogeneity in treatment response • Pragmatic trials
Investigators at or above the level of Assistant Professor (or equivalent) may be named by the organization as the PI on the application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY21 ARP Clinical Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.